Found 147 results
[ Type(Desc)] Year
L Holtzman, and CA Gersbach. Editing the Epigenome: Reshaping the Genomic Landscape.. Vol. 19., 2018.
AA Abdeen, BD Cosgrove, CA Gersbach, and K Saha. Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science.. Vol. 23., 2021.
Conference Paper
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "59. Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
KA Glass, AK Ross, SA Compton, CA Gersbach, FT Moutos, BT Estes, and F Guilak. "Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Inflammatory Capabilities." In Tissue Engineering. Part A, S330. Vol. 21. 2015.
N Farhang, JM Brunger, JD Stover, PI Thakore, BD Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In Tissue Engineering. Part A, S170. Vol. 21. 2015.
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
E Schulz, T Bergmann, M Gebbing, V Schildgen, O Schildgen, C Gersbach, and A Ehrhardt. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In Molecular Therapy, S126-S127. Vol. 22. 2014.
P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, GE Crawford, AJ Hartemink, and CA Gersbach. "Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In Molecular Therapy, S93. Vol. 21. 2013.
A Pickar-Oliver, JB Black, MM Lewis, KJ Mutchnick, TS Klann, KA Gilcrest, MJ Sitton, CE Nelson, A Barrera, LC Bartelt et al. "Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells." In Nat Biotechnol, 1493-1501. Vol. 37. 2019.
KA Glass, JM Brunger, CA Gersbach, and F Guilak. "Tunable expression of IL-1Ra in genetically modified mesenchymal stem cells for cartilage tissue engineering." In Osteoarthritis and Cartilage, S282-S283. Vol. 21. 2013.
Journal Article
CH Hakim, NB Wasala, CE Nelson, LP Wasala, Y Yue, JA Louderman, TB Lessa, A Dai, K Zhang, GJ Jenkins et al. "AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice." Jci Insight 3, no. 23 (2018).
ME Nance, R Shi, CH Hakim, NB Wasala, Y Yue, X Pan, T Zhang, CA Robinson, SX Duan, G Yao et al. "AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice." Molecular Therapy 27, no. 9 (2019): 1568-1585.
CA Gersbach, and P Perez-Pinera. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 835-839.
AJ García, RE Guldberg, BA Byers, CA Gersbach, and JE Phillips. "Addressing cell-sourcing limitations with gene therapy." Ieee Engineering in Medicine and Biology Magazine : the Quarterly Magazine of the Engineering in Medicine & Biology Society 22, no. 5 (2003): 65-70.
P Perez-Pinera, DG Ousterout, and CA Gersbach. "Advances in targeted genome editing." Current Opinion in Chemical Biology 16, no. 3-4 (2012): 268-277.
FT Moutos, KA Glass, SA Compton, AK Ross, CA Gersbach, F Guilak, and BT Estes. "Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of the United States of America 113, no. 31 (2016): E4513-E4522.
BC Evans, RB Fletcher, KV Kilchrist, EA Dailing, AJ Mukalel, JM Colazo, M Oliver, J Cheung-Flynn, CM Brophy, JW Tierney et al. "An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles." Nature Communications 10, no. 1 (2019).
J Seo, DD Kocak, LC Bartelt, CA Williams, A Barrera, CA Gersbach, and TE Reddy. "AP-1 subunits converge promiscuously at enhancers to potentiate transcription." Genome Res 31, no. 4 (2021): 538-550.
GP Pathak, JI Spiltoir, C Höglund, LR Polstein, S Heine-Koskinen, CA Gersbach, J Rossi, and CL Tucker. "Bidirectional approaches for optogenetic regulation of gene expression in mammalian cells using Arabidopsis cryptochrome 2." Nucleic Acids Research 45, no. 20 (2017).
CA Gersbach,, JM Le Doux, and AJ García. "Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (2007): 5121-5127.
M Gemberling, and CA Gersbach. "Boosting, Not Breaking: CRISPR Activators Treat Disease Models." Molecular Therapy 26, no. 2 (2018): 334-336.
JM Walejko, BA Christopher, SB Crown, G-F Zhang, A Pickar-Oliver, T Yoneshiro, MW Foster, S Page, S van Vliet, O Ilkayeva et al. "Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart." Nature Communications 12, no. 1 (2021).
CE Nelson, and CA Gersbach. "Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (2016): 298-299.
CH Hakim, SRP Kumar, DO Pérez-López, NB Wasala, D Zhang, Y Yue, J Teixeira, X Pan, K Zhang, ED Million et al. "Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models." Nature Communications 12, no. 1 (2021).
L Wang, E Wang, Prado J Balcazar, Z Wu, K Xiang, Y Wang, Q Huang, M Negrete, K-Y Chen, W Li et al. "Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis." Advanced Science (Weinheim, Baden Wurttemberg, Germany) 8, no. 19 (2021).